Turing
FDA clears generic of Daraprim, the ‘poster drug’ for price-gouging
Drug hit headlines after price jumped from $13.50 to $750 overnight
France’s Innate Pharma eyes $100m Nasdaq IPO
Would help fund development of antibody-based immunotherapies
‘Missing protein’ biotech Stoke raises $142m in IPO
Continues pioneering research
Theranos and its CEO settle ‘massive fraud’ charges
SEC says case is a lesson in truth-telling for those seeking to disrupt an industry
Post-Shkreli KaloBios pledges transparent pricing
Will seek input from “key stakeholders” and share reasoning behind pricing of drugs
KaloBios files for bankruptcy protection
San Francisco biopharma's shares imploded in the wake of Martin Shkreli's arrest
Shkreli fallout claims Turing jobs and KaloBios’ listing
Both firms continue to suffer with job cuts and de-listing from the Nasdaq
Update: Shkreli resigns as Turing CEO, ousted from KaloBios
Shares in KaloBios had been hit hard when news of his arrest broke
Turing CEO Shkreli arrested by FBI in securities fraud probe
Accused of illegally using stock from biopharma firm Retrophin to pay off debts
Express Scripts to offer alternative to Turing’s Daraprim
Andpromises to share compounded formulation with other healthcare payers
Bio investors react as Clinton tweet pledges pricing crackdown
Pharma companies come under scrutiny for pricing policies